Non-small cell lung cancer stories

Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 20262 sources

Sep 13, 2026

Multimodal AI model outperforms established biomarkers for immunotherapy in lung cancer

A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.

Sep 13, 20262 sources

Top claims

▪In the HARMONi-2 trial, patients with high PD-L1 expression of 50% or greater achieved a median overall survival that was not reached with ivonescimab compared to 23.2 months with pembrolizumab
▪Dr. Mariana Brandão cautioned that the control arm of pembrolizumab monotherapy in the phase 3 HARMONi-2 trial of ivonescimab versus pembrolizumab in PD-L1-positive advanced non-small cell lung cancer does not reflect global clinical practice, where anti-PD-1 therapy is typically combined with chemotherapy
▪In the phase 3 HARMONi-2 trial comparing ivonescimab with pembrolizumab in PD-L1-positive advanced non-small cell lung cancer, in the subgroup with PD-L1 expression of 1% to 49%, median overall survival was 28.5 months with ivonescimab compared to 22.1 months with pembrolizumab

Topics

Immunotherapy Drug Approval and Clinical Trials Clinical trials Cancer treatment breakthroughs Cancer treatment Multimodal models AI in healthcare Clinical decision support AI interpretability

Related entities

Pembrolizumab Lung cancer Immunotherapy